arrow
S

Sergei Timofeevski

Pfizer
H指数:24
被引数:4,637

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Discovery of PF-07265028, A Selective Small Molecule Inhibitor of Hematopoietic Progenitor Kinase 1 (HPK1) for the Treatment of Cancer
2024-12-090
PRE
Discovery of Highly Selective Inhibitors of Microtubule-Associated Serine/Threonine Kinase-like (MASTL)
2024-11-050
PRE
MASTL small-molecule inhibition to target mitosis for cancer therapy
2024-03-220
PRE
Design and Synthesis of Functionally Active 5-Amino-6-Aryl Pyrrolopyrimidine Inhibitors of Hematopoietic Progenitor Kinase 1
2023-03-2019
PRE
A HIGHLY-SELECTIVE HPK1 INHIBITOR ENHANCES T CELL RECEPTOR SIGNALING AND T CELL ACTIVATION POTENTIAL, INCREASING ANTIGEN RECOGNITION AND EFFICACY OF PD-1 THERAPY
2022-12-080
OA
INHIBITION OF P21-ACTIVATED KINASE 4 (PAK4) REVERTS IMMUNE EXCLUSION AND RESTORES ANTITUMOR IMMUNITY IN THE TUMOR MICROENVIRONMENT
2021-11-100
OA
Structure-Based Drug Design and Synthesis of PI3Kα-Selective Inhibitor (PF-06843195)
2020-12-2426
PREAI
Characterization of Specific N-α-Acetyltransferase 50 (Naa50) Inhibitors Identified Using a DNA Encoded Library
2020-04-1023
OAAI
Sequential ALK Inhibitors Can Select for Lorlatinib-Resistant Compound ALK Mutations in ALK-Positive Lung Cancer
2018-05-31237
OAAI
Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F
2016-01-07427
OA
PF-06463922, a novel next generation ALK/ROS1 inhibitor, overcomes resistance to 1st and 2nd generation ALK inhibitors in pre-clinical models
2015-08-010
PRE
PF-06463922 is a potent and selective next-generation ROS1/ALK inhibitor capable of blocking crizotinib-resistant ROS1 mutations

PF-06463922是一种有效且选择性的新一代ROS1/ALK抑制剂,能够阻断对克唑替尼耐药的ROS1突变

2015-03-02263
OAAI
Discovery of (10R)-7-Amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo[4,3-h][2,5,11]-benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a Macrocyclic Inhibitor of Anaplastic Lymphoma Kinase (ALK) and c-ros Oncogene 1 (ROS1) with Preclinical Brain Exposure and Broad-Spectrum Potency against ALK-Resistant Mutations
2014-06-03524
PREAI
Design of Potent and Selective Inhibitors to Overcome Clinical Anaplastic Lymphoma Kinase Mutations Resistant to Crizotinib
2014-02-06110
OA
PF-06463922, a novel ROS1/ALK inhibitor, demonstrates sub-nanomolar potency against oncogenic ROS1 fusions and capable of blocking the resistant ROS1G2032R mutant in preclinical tumor models.
2013-11-017
PRE
PF-06463922, a novel brain-penetrating small molecule inhibitor of ALK/ROS1 with potent activity against a broad spectrum of ALK resistant mutations in preclinical models in vitro and in vivo
2013-11-016
PRE